O'Hagan DT, Wack A, Podda A (2007) MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther 82:740-744. doi:10.1038/sj.clpt.6100402O'Hagan DT, Wack A, Podda A (2007) MF59 is a safe and potent vaccine ...
Antigen and adjuvant dose and type Combinations and co-administration Symptom management Full size image Redness and mild swelling are not usually associated with significant discomfort and usually require no treatment or can be managed with local application of ice. Pain in the days following injection...
In recent years, major advances have been made in CMV prevention and treatment in transplant recipients. Rigorous research is ongoing and is anticipated to further impact our ability to improve outcomes in this population. Anat Stern declares that she has no conflict of interest. Genovefa Papanicola...
Pandemrix, produced by GlaxoSmithKline (GSK) in Dresden, Germany, contained the adjuvant AS03, which is a mix of squalene and α-tocopherol [22]. This same AS03 adjuvant had been previously included in avian influenza H5 and H7 vaccines where its safety and immunogenicity had been tested in ...
No studies have identified an increased risk of narcolepsy following the MF59-adjuvanted Focetria vaccine. For many potential pandemic influenza strains, adjuvants might be required to solicit a protective immune response. Thus, it is critical that we understand the nature of the association between ...
Some of the advantages of GMVs in vaccination are the enhancement of immunogenicity without an adjuvant and induction of robust cytotoxic T lymphocyte response to eliminate virus-infected cells. Many viruses have been used as GMVs for vaccination purposes, the major ones being Poxviridae (Vaccinia ...